HeartBeat Health 

Coronary computed tomography angiography (CCTA) is a heart-specific diagnostic imaging test that helps determine if plaque buildup has narrowed the coronary arteries, the blood vessels that supply the heart. Computed tomography is more commonly known as a CT or CAT scan. Like traditional x-rays, it produces multiple images or pictures of the inside of the body. A CT scan generates images that can be reformatted in multiple planes and can even generate three-dimensional images. Patients undergoing a CCTA scan receive an iodine-containing contrast material as an intravenous (IV) injection to ensure the best possible images of the heart blood vessels.

The Cleerly coronary analysis is a thorough evaluation of the presence, amount, and type of plaque in the heart’s arteries based on a CCTA study. Images captured in the CCTA exam are processed by Cleerly software – a set of artificial intelligence-based algorithms – and translated into measurements and reports for review by the patient’s physician. The results of the Cleerly analysis give a patient and their physician a comprehensive understanding of the patient’s current state of disease for reference in the patient’s ongoing heart health and treatment.

Plaque is the physical representation of a disease called atherosclerosis. It is made of various substances such as fat, cholesterol and calcium that deposit along the inner lining of the arteries. Plaque, which builds up over time, can reduce or in some cases completely block blood flow. The presence and type of plaque in the coronary arteries has proven to be the strongest discriminant of future heart attack risk and perhaps the greatest indicator of an impending cardiac event.

Cleerly’s AI-powered software allows providers to spot signs of heart disease without requiring the invasive evaluations that make up the current gold standard for coronary artery disease diagnosis. Cleerly’s AI analyzes noninvasive coronary CT scans to measure the amount of plaque build-up in the coronary arteries. The aim is to detect heart disease before symptoms arise, which is important as the first symptom for more than half of coronary artery disease patients is a heart attack.

Cleerly is expanding access to our new standard of precision heart care through our partnership with Heartbeat Health, now available to patients in all 50 states.

Cleerly is available for patients with known or suspected heart disease, or anyone who wants to learn more about their heart health and get ahead of potential heart disease.

A Cleerly analysis is used to detect the type and amount of atherosclerotic plaque in your coronary arteries. The three types of plaque are low density plaque, non-calcified plaque, and calcified plaque.

Low density plaque has the highest risk of future cardiac events. Non-calcified plaque also has risk associated with it, and calcified plaque is considered relatively benign.

If you have plaque, your provider can use Cleerly analysis to personalize treatment and help assess your risk of a future attack.

Cleerly’s quantitative outputs have been validated in a series of six multicenter clinical trials, which we call the CLARIFY trials. These include validation against expert level 3 clinical readers, quantitative coronary angiography (QCA), intravascular ultrasound (IVUS), optical coherence tomography (OCT), near field infrared spectrocity (NRIS), and invasive fractional reserve (FFR). These are current gold standards for heart disease evaluation.